Focal Segmental Glomerulosclerosis (FSGS) Pipeline Insight Report 2020: Comprehensive Insights About 15+ Companies and 15+ Pipeline Drugs - ResearchAndMarkets.com
b'This segment of the Focal Segmental Glomerulosclerosis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery.
- b'This segment of the Focal Segmental Glomerulosclerosis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery.
- Retrophin is examining the ability of sparsentan to slow the decline of kidney function in patients with FSGS and IgAN.
- It is a single molecule designed to be a dual endothelin receptor type A (ETA) and angiotensin II receptor type 1 (AT1) antagonist.
- It is currently in phase II stage of development.\nDelta 4 is working on its lead program which aims at developing a therapy for Focal Segmental Glomerulosclerosis (FSGS).